To date, only 20-30% of acute myeloid leukemia (AML) patients escape relapse to achieve long-term survival, 1 demonstrating the crucial need for new targeted therapies.
The nuclear factor-kB (NF-kB) transcription factor is an attractive potential therapeutical target as it is found aberrantly activated in many solid tumors and hematologic malignancies to support abnormal proliferation and resistance to apoptosis triggered by therapeutic agents. [2] [3] [4] We previously observed that the IkB kinase 2 inhibitor AS602868 could prevent constitutive NF-kB activation in primary AML cells and, as a consequence, was able to induce apoptosis in vitro and to potentiate the apoptotic effects of standard chemotherapeutic drugs such as doxorubucin, AraC and VP-16. 5 Constitutive NF-kB has been observed in a large proportion of AML cases, 52 of 76 in three independent studies [6] [7] [8] and was associated with permanent activation of the IkB kinase complex. 7 A large number of studies can be considered as proof of concept for translating an NF-kB inhibition strategy from bench to bedside (see Gilmore and Herscovitch 9 for review). Next, we discovered that AS602868 could interfere directly with activation of the Fms-like tyrosine kinase 3 (FLT3), 10 an important receptor on myeloid and lymphoid progenitors, which promotes their proliferation, differentiation and survival. 11, 12 FLT3 is overexpressed or mutated in a large number of AML cases 13 and the internal tandem duplication (ITD) mutant is associated with poor survival.
14 An additional and crucial aspect of AML physiopathology is the existence of leukemic stem cells (LSC), which generate leukemic blasts and are responsible for relapse. 15 Interestingly, NF-kB is abnormally activated in AML-LSC 16 and inhibiting NF-kB with a proteasome inhibitor 16 or with parthenolide 17 could interfere with AML survival and engraftment in NOD-SCID mice, suggesting that these treatments could target LSC.
In addition, FLT3 is expressed in CD34 þ CD38À stem cell-enriched fractions from AML samples suggesting that the mutant receptor could participate in growth and survival of LSCs.
18 AS602868 could therefore represent an interesting molecule to target primitive leukemic cells by affecting both NF-kB and FLT3, as to date FLT3 inhibitors have shown limited clinical potential. 19 In this study, we have evaluated the potential of AS602868 at various developmental stages of either normal CD34 þ cord blood or AML cells through different functional assays. A leukemic AML clone displays a hierarchical organization state with variable self-renewal, proliferation and differentiation potential. 15, 20, 21 At the root of the clone are LSCs that can be visualized by AML reconstitution in immunodeficient NOD-SCID mice. 22 These cells generate primitive progenitors, analyzed using the long-term culture-initiating cell method. 20 Finally, less primitive acute myelogenous leukemia colonyforming cells (CFU) can be assessed through colony formation in clonogenic assays using semisolid medium. 23 We have first investigated the effects of AS602868 on the clonogenic property of five AML patient samples and six normal CD34 þ samples (five cord blood, one bone marrow). Cells were cultured for 14 days in methyl cellulose semisolid medium in the presence of cytokines without or with 10 mM AS602868 before counting myeloid and erythroid colonies (for Materials and methods see Supplementary information 1). Treatment with 10 mM AS602868 decreased the number of normal and acute myelogenous leukemia colony-forming cells by 40 and 76%, respectively ( Figure 1a ). AS602868 also significantly reduced the size of colonies, from both normal ( Figure 1b ) and AML samples ( Figure 1c) . AML samples, which give smaller colonies than cord blood cells, were cultured for an additional 10 days to further highlight the effect of AS602868 on colony size. A cell cycle analysis on normal colonies showed an increased number of cells in the G0/G1 phases (85.2 vs 58.4%) after AS602868 treatment ( Figure 2d ). Quantitative real-time PCR analysis showed that the inhibitor decreased the amount of mRNA species for the two NF-kB target genes IkB-a and cyclin D1 (Supplementary Table 1 ), which is consistent with an inhibition of NF-kB-dependent transactivation and could also explain the reduction in colony size.
To evaluate the possible toxicity of the molecule, AS602868 was administrated at 100 mg kg À1 (5 days per week) to NMRI nude or C57BL/6 mice. After 3 weeks of treatment, the differentiation potential of bone marrow cells was analyzed as above. In both strains, AS602868 did not affect the number (Supplementary Figure 1) nor the size of CFU colonies (not shown) suggesting that the inhibitor did not exert major toxicity on normal hematopoiesis in vivo. In addition, no particular hematopoietic toxicity of the compound was reported during drug development (data not shown).
Bulk culture long-term culture-initiating cell assays were next conducted to analyze the effect of targeting NF-kB and FLT3 in more primitive progenitors (Figure 2a) . Human AML or CD34 þ normal cells were cocultured with irradiated M210B4 murine feeder cells and left untreated or incubated with 10 mM AS602868. After 4 additional weeks in culture, the clonogenic potential of surviving precursors was tested in a colony-forming cell assay. Within five different AML samples, an important decrease in colony-forming cell formation was observed, reflecting a lower number of primitive progenitors in the culture upon incubation with AS602868 ( Figure 2a) . By contrast, AS602868 had a minimal effect on normal cord blood samples. While the number of colony-forming cells increased with the number of cells seeded in the assay, augmenting the amount of normal cells frequently interfered with colony formation as evidenced by the second cord blood sample. Then, the in vivo potential of AS602868 was evaluated in recolonization experiments using AML or CD34 þ normal cells injected in the tail vein of irradiated immunodeficient NOD-SCID mice, the goldstandard assay for functional analysis of stem cells. Three experiments were performed with cells derived from two AML patients and one with normal cells corresponding to pooled preparations of CD34 þ cells from several cord blood samples. Human cells were monitored and quantified by fluorescentactivated cell sorting analysis in peripheral blood after staining with anti-CD45 human-specific antibodies. When CD45 þ cells became detectable, mice were treated with vehicle or AS602868 (30 mg kg À1 ) for 4 or 6 weeks as indicated. CD45-positive cells were quantified in the bone marrow by flow cytometry. The percentage of engraftment ranging from 36.5 to 61.9% strongly decreased to 13.4-26.9% after treatment with AS602868 (Figure 2b ). This decrease in the number of leukemic blasts in the bone marrow could be observed after May-Grü nwald Giemsa staining (Figure 2e) .
Within three experiments, a total of 12 mice in control condition had a mean percentage of engraftment of CD45 þ cells at 47.0±25.3, that decreased to 17.6±12.9 in 15 AS602868-treated mice (Supplementary Table 2 ). In sharp contrast, AS602868 did not interfere with, and even slightly increased, the engraftment of normal cord blood cells (38.5 vs 26.1%). It would be tempting to speculate that AS602868 targets leukemic stem cells. While it is clear that AS602868 action is going deeper in the hierarchy of the leukemic clone, we cannot rule out that these effects could only be due to the elimination of AML colony-forming cells or AML blasts and that AML-LSC have survived the treatment. Serial transplantations of AML cells in NOD-SCID mice will be absolutely required to evaluate the true capacity of the drug to eliminate AML-LSC.
Altogether, our results in various functional assays show a clear preferential effect of AS602868 on AML cells compared to cord blood hematopoietic stem cell. This could be surprising at first glance when considering the important physiological functions of NF-kB and FLT3 that are targeted by AS602868. A reasonable explanation would be an oncogenic dependence developed by AML cells toward the pathologic activation of these two pathways that makes them sensitive to AS602868, compared with normal cells. Along this line, an interesting report 19 has shown that the combination of the FLT3 inhibitor PKC412 with conventional antileukemic drugs showed synergistic effects in cells with mutated FLT3, while it was antagonist on FLT3-negative lines. It would be highly interesting to evaluate in a future clinical trial whether the effect of AS602868 varies depending on the FLT3 status of the patients.
We are nevertheless convinced that inhibition of NF-kB/FLT3, or the use of any other single drug directed against any molecular defects will not be sufficient to eliminate LSC. Studies are suggesting that the combination of several drugs targeting several oncogenic events will be required to see significant advances in AML and other cancers. 24 As NF-kB is activated by most chemotherapeutic drugs and provides protection against drug-induced cell death, combining NF-kB inhibition with classic chemotherapy is expected to potentiate the effects of the treatment as already demonstrated in several models.
Figure 1
Clonogenic potential of AML and normal CD34 after in vitro treatment with AS602868. (a) Cells were incubated with 10 mM AS602868 for 14 (normal cells) or 24 (AML) days in methylcellulose semisolid medium. Six normal CD34 specimens from five cord blood and one bone marrow and five AML specimens were compared. Mean and s.e.m. are displayed. Each point represents the average value for one specimen (triplicate) normalized to untreated control. The data were analyzed by 1-way ANOVA followed by t-test (P ¼ 0.00534). (b, c) Size of normal CFU-GM and BFU-E (b) and AML-CFU (c) colonies. Scale bar represents 200 mM (normal colonies) or 800 mM (AML colonies). Note that the control AML-CFU picture (left) is a composite of four pictures obtained with the same magnification as for the AS602868 sample (right) (d) Cell cycle analysis by flow cytometry of erythroid colonies removed from the normal and AS602868 treated conditions. Area definition of DNA histogram: M1: Go/G1 phases, M2: G2/M phases, M3: S phase, M4: subdiploïd DNA. The percentage of cells in the G0/G1 phase is displayed. AML, acute myeloid leukemia; AML-CFU, acute myelogenous leukemia colony-forming cells; ANOVA, analysis of variance; BFU-E, burst-forming units-erythroid; CFU-GM, colony-forming units granulocyte-macrophage.
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We are grateful to Dr Frederic Mazurier (INSERM U876, Bordeaux, France) for very helpful discussion and advice concerning mouse engraftment experiments. We thank Dr Samantha Sarno (EMD-Serono, Boston, MA, USA) for constructive comments and critical review of the manuscript and Dr Virginie Bottero for statistical analysis. This work was supported by the Acute promyelocytic leukemia (APL) is characterized by a recurrent translocation between chromosomes 15 and 17, resulting in the fusion of the promyelocytic leukemia gene (PML) to the retinoic acid receptor a gene (RARa). 1 Among APL cases with a PML-RARa rearrangement, chromosome 15 breakpoints fall within three breakpoint cluster regions (bcrs): bcr1 and bcr3 correspond to PML introns 6 and 3, respectively, whereas bcr2 is located within PML exon 6, or very occasionally within PML exon 5. On the contrary, a single RARa breakpoint region occurs within intron 2.
2
A bcr1 breakpoint is reported in approximately 55% of patients and results in an mRNA fusion of PML exon 6 to RARa exon 3, conventionally referred to as the long (L) isoform. A bcr3 breakpoint occurs in approximately 40% of cases and results in an mRNA fusion of PML exon 3 to RARa exon 3, referred to as the short (S) isoform. A bcr2 breakpoint occurs in approximately 5% of patients and usually results in a tripartite mRNA fusion in which part of PML exon 6 is fused to an insert sequence and then to RARa exon 3, where the insert is usually between 3 and 127 base pairs long and has been presumed to be derived from RARa intron 2. Some cases have no inserted nucleotides and instead use a cryptic splice site within PML exon 6 to splice part of this exon in frame to RARa exon 3. Collectively, these transcripts are referred to as the variable (V) isoform. [2] [3] We report an APL case showing a different genomic and molecular rearrangement at relapse from those observed at the onset of disease.
A 39-year-old man was admitted to our hospital in October 2002 with hematuria and diffuse bruising. Blood analysis
